Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 5, 2006, Pages 263-264

  Senba, Hiroaki ^a   Kawano, Mikihiko ^a   Kawakami, Masanobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE;

BLOOD; CASE REPORT; DRUG COMBINATION; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; LETTER; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 34247890978     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.263     Document Type: Article

References (4)

1. Ebcioglu Z, Morgan J, Carey C, and Capuzzi D: Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med, 2003; 139:W80
2. Sarker A, Semple RK, Dinneen AF, O'Rahilly S, and Martin SC: Severe hypo-α-lipoproteinemia during treatment with rosiglitazone. Diabetes Care, 2005; 27:2577-25808
3. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, and Staels B: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem, 1994; 269:31012-31018
4. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, and Staels B: The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem, 1998: 273:25713-25720